Alterity Therapeutics (NASDAQ: ATHE) plans 150M service-linked options

Rhea-AI Filing Summary

Alterity Therapeutics Limited has reported a proposed issue of 150,000,000 options as payment for services to Lawrence Gozlan and Chairman Julian Babarczy. The options have an exercise price of A$0.02 and expire five years after issue, with an expected expiry date of 26/6/2031.

The options are to be issued for non-cash consideration, with each option exercisable into one fully paid ordinary share. The proposed issue date is 26/6/2026 and is subject to shareholder approval at a meeting scheduled for 27/5/2026 under ASX Listing Rule 7.1.

Insights

Equity compensation analyst

Alterity plans a large, service-based option grant subject to shareholder approval.

Alterity Therapeutics proposes issuing 150,000,000 options with a A$0.02 exercise price, expiring on 26/6/2031. Each option converts into one ordinary share, and the grant serves as payment for services to Lawrence Gozlan and Chairman Julian Babarczy.

The options are being issued for non-cash consideration, which aligns this compensation directly with potential future equity value rather than immediate cash outlay. All options in the class will rank equally from issue.

The issue is conditional on shareholder approval under ASX Listing Rule 7.1 at a meeting scheduled for 27/5/2026, with a proposed issue date of 26/6/2026. Subsequent company disclosures may clarify the final terms and any impact once approval and issuance occur.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Proposed issue of securities - ATH

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: March 19, 2026

2

Exhibit 99.1

Appendix 3B - Proposed issue of securities

Announcement Summary

Entity name

ALTERITY THERAPEUTICS LIMITED

Announcement Type

New announcement

Date of this announcement

19/3/2026

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code		+Security description		Maximum Number of +securities to be issued
New class-code to be confirmed		Options with expiry date five (5) years after date of issue and exercise price of A$0.02.		150,000,000

Proposed +issue date

26/6/2026

Refer to next page for full details of the announcement 

Appendix 3B - Proposed issue of securities 1/5

Appendix 3B - Proposed issue of securities

Part 1 - Entity and announcement details

1.1 Name of +Entity

ALTERITY THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

	1.2 Registered Number Type		Registration Number
	ABN		37080699065

1.3 ASX issuer code

ATH

1.4 The announcement is

New announcement

1.5 Date of this announcement

19/3/2026

1.6 The Proposed issue is:

A placement or other type of issue

Appendix 3B - Proposed issue of securities 2/5

Appendix 3B - Proposed issue of securities

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

	Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
	+Security holder approval	27/5/2026	Estimated

Comments

Part 7B - Issue details 

Is the proposed security a ‘New class’ (+securities in a class that is not yet quoted or recorded by ASX) or an ‘Existing class’ (additional securities in a class that is already quoted or recorded by ASX)? New class Will the proposed issue of this +security include an offer of attaching +securities? No

Details of +securities proposed to be issued 

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1? No Will the entity be seeking quotation of the ‘new’ class of +securities on ASX? No

	ASX +security code		+Security description
	New class-code to be confirmed		Options with expiry date five (5) years after date of issue and exercise price of A$0.02.

+Security type 

Options

Number of +securities proposed to be issued 

150,000,000

Appendix 3B - Proposed issue of securities 3/5

Appendix 3B - Proposed issue of securities

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

No consideration provided.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

0.0000001

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Options details

	+Security currency	Exercise price	Expiry date
	AUD - Australian Dollar	AUD 0.0200	26/6/2031

Details of the type of +security that will be issued if the option is exercised

ATH : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One fully paid ordinary share (ASX:ATH)

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities

proposed to be issued or provide the information by separate announcement.

To be provided in the future Notice of Meeting announcement.

Part 7C - Timetable

7C.1 Proposed +issue date 2

26/6/2026

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

27/5/2026

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

Appendix 3B - Proposed issue of securities 4/5

Appendix 3B - Proposed issue of securities

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

No

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Payment for services rendered for Lawrence Gozlan and Julian Babarczy.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

Appendix 3B - Proposed issue of securities 5/5

FAQ

What securities is Alterity Therapeutics (ATHE) proposing to issue?

Alterity Therapeutics proposes issuing 150,000,000 options as a placement or other type of issue. Each option has a A$0.02 exercise price and converts into one fully paid ordinary share if exercised, expiring five years after the issue date on 26/6/2031.

What is the purpose of the new options issued by Alterity Therapeutics (ATHE)?

The options are being issued as payment for services rendered to Lawrence Gozlan and Chairman Julian Babarczy. This structure provides non-cash compensation that ties their benefits to the company’s future share performance through the A$0.02 exercise price and five-year option term.

When will the Alterity Therapeutics (ATHE) options be issued and when do they expire?

The proposed issue date for the 150,000,000 options is 26/6/2026, subject to approval. The options have a five-year term from issue, with the filing identifying an expected expiry date of 26/6/2031, after which they can no longer be exercised for shares.

Is shareholder approval required for the Alterity Therapeutics (ATHE) option issue?

Yes. The proposed option issue is conditional on security holder approval under ASX Listing Rule 7.1. A shareholder meeting is scheduled for 27/5/2026 to consider the approval, and the issue can proceed on an unconditional basis only if that approval is obtained.

Are the new Alterity Therapeutics (ATHE) options being issued for cash consideration?

No. The options are not being issued for cash; they are compensation for services. The filing notes non-cash consideration with an estimated nominal AUD value and states the purpose is payment for services rendered to Lawrence Gozlan and Julian Babarczy.

What class of securities will Alterity Therapeutics (ATHE) issue on option exercise?

On exercise, each option will result in the issue of one ATH ordinary fully paid share. All options in this new class will rank equally from the issue date, and the options carry a fixed exercise price of A$0.02 according to the disclosed terms.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PROPOSED ISSUE OF SECURITIES - ATH 35.7 KB